| INTRODUC TI ON
Bipolar disorder is the sixth leading cause of disability worldwide, and its early onset and chronic nature underscore its cumulative illness burden and the importance of early intervention and optimal disease management strategies.
1,2 However, lack of access to and minimal utilization of healthcare coupled with low socioeconomic status continue to drive disease-related disability worldwide, including in the USA. In comparison to the general US population, Americans with mental illness have decreased life expectancy; for people with severe mental disorders (i.e. schizophrenia, depression, and bipolar disorder), this life expectancy reduction ranges from 10 to 20 years. 3, 4 There is a general recognition that the increased morbidity and mortality of people with serious mental illness may be magnified by racial disparities in access to, or provision of healthcare. AfricanAmerican individuals with bipolar disorder, in comparison to white individuals with bipolar disorder, have been reported to have significantly higher rates of receiving an initial clinical diagnosis other than bipolar disorder; this misdiagnosis may impede treatment strategies that can directly address illness morbidity.
5-7
The patient advocacy group Depression Bipolar Support Alliance To accomplish this goal, we reviewed literature pertaining to diagnosis and treatment of bipolar disorder (either type I or type II) in people of African ancestry compared with people of non-African ancestry. Barriers to research inclusion and participation are also discussed, especially in the context of genetic research, underscoring the need to address potential racial biases during diagnosis and treatment, and the potential hazards of not doing so. We first present the literature chronologically to evaluate how recognition of this problem has evolved over the last 50 years. We then explore the potential effects of misdiagnosis on outcome and prognosis, and posit genomic studies of bipolar disorder as a possible method of addressing this disparity.
| ME THODS
Literature for this descriptive review was selected using key search terms to target studies describing diagnostic, treatment, and outcome differences between individuals of European and African ancestry, and research participation in biological research, specifically genetic studies, among people of African and European ancestry.
The cited literature came from PubMed and Google Scholar searches with the following key terms: bipolar disorder African Americans, bipolar disorder African Americans treatment, bipolar disorder African ancestry, bipolar disorder African Americans lithium, and bipolar disorder blacks. To identify genetic studies, these keywords were searched for: bipolar disorder African ancestry genetics. A total of 28 publications were excluded from the initial search, and 20 more were excluded based on pertinent content, the details of which are shown in Figure 1 .
We retained the language used in the original publications to describe various racial and ethnic identifications; for example, if a publication described patients of African ancestry as 'African American', the term 'African American' was used when discussing the publication. In addition, race and ethnicity are terms often used interchangeably. The Oxford Dictionary defines ethnicity as 'the fact or state of belonging to a social group that has a common national or cultural tradition', while defining race as 'each of the major divisions of humankind, having distinct physical characteristics… a group of people sharing the same culture, history, language, etc.; an ethnic group.' 10 These definitions are very similar to each other and important genomic studies. This gap in biological research in this underrepresented minority may represent a missed opportunity to address potential racial differences in the risk and course of bipolar illness.
Conclusion:
A concerted effort by the research community to increase inclusion of diverse persons in studies of bipolar disorder through community engagement may facilitate fully addressing these diagnostic and treatment disparities in bipolar individuals of African ancestry.
K E Y W O R D S
bipolar disorder, African ancestry, health/racial disparities, minority research participation we therefore use the terms interchangeably and retain the language used (either race or ethnicity) in the cited studies.
| E VOLUTI ON OF D IAG NOS TI C CRITERIA AND HIS TORI C AL S TUD IE S OF P OTENTIAL R ACIAL B IA S
Psychiatric diagnostic classification has been achieved glob- for potential demographic confounds. Furthermore, the lack of significant ethnic differences in positive and negative moderate symptom severity also suggests equivalent symptom burden but different clinical interpretation of diagnostic information. While these historical studies identify racial/ethnic bias as a contributor to misdiagnosis, more contemporary research (with enhanced study methodology) may suggest strategies to correct for these differences.
The Epidemiologic Catchment Area Study (ECA) was a landmark study that examined the utilization of a structured diagnostic inter- While the percentage of black respondents at each site ranged from 4% to 34%, there was no significant difference in rates of bipolar disorder by race, suggesting the value of a highly structured research diagnostic interview as a data source to reduce clinical interpretative differences among persons of different races and ethnicities. with bipolar disorder had significantly higher rates of clinical schizophrenia diagnoses (25% vs 7%, respectively; P = .02) and higher rates of schizophrenia diagnosis by structured interview (29% vs 15%; P < .03) when compared to the other patient groups.
Rates of first-rank psychotic symptoms did not differ by ethnic group, suggesting that the patient's race and sex were primary factors for schizophrenia diagnosis. 20 The use of an expert panel reviewing diagnostic criteria, in comparison to both clinical diagnosis and structured interview, appeared to yield less misdiagnosis.
The evolution of bipolar disorder diagnostic criteria coincides with these inaugural efforts to understand differences in diagnosis between bipolar individuals of European and African ancestry. Reports suggest that these differences are mainly attributable to racial/ethnic bias and/ or misattribution of psychotic symptoms. These historical and distinctive studies are key to understanding the development of this disparity and its impact on subsequent treatment ( Figure 2 ).
| TRE ATMENT, RE S P ON S E , AND PROG NOS IS
A 2002 prospective longitudinal study reported that 24 AfricanAmericans with bipolar I disorder received antipsychotics at a 
| G ENOMI C S TUD IE S OF B IP OL AR DISORDER : UNDERREPRE S ENTATION OF P OPUL ATIONS OF AFRIC AN AN CE S TRY
Understanding the genetic basis of bipolar disorder could greatly advance knowledge of its neurobiology and etiology. Bipolar disorder is a complex genetic disorder, with heritability estimated to be between 60% and 85%, indicating that a large proportion of disease risk is potentially attributed to inter-individual genetic variation. 33 Numerous studies have attempted to identify genetic factors contributing to the risk of bipolar disorder to uncover the underlying pathophysiology and pathogenesis of the disease. While genomic research could aid in resolving health disparities, others have argued that knowledge of genetic factors that contribute to illness or treatment outcomes will not itself reduce health disparities. Kashyap and colleagues note that, although the role of genomics in health disparities is quite complex, it is critical to understand how genetic variation influences the health and well-being of at-risk communities to eliminate health disparities in the USA. 34 On the other hand, West et al. 35 argue that clarification of genetic contributors to disease etiology will not help to provide ways to address disparities, as they are rooted in social, material, and environmental conditions. Nevertheless, there is recognition that genetic studies should include diverse populations to enable identification of a wide range of genetic variation contributing to health outcomes and ensure that knowledge gained from these studies is applicable to all populations.
Numerous studies have been conducted to investigate the genetics of bipolar disorder, including many candidate gene studies, a growing number of genome-wide association studies (GWASs), and recently introduced whole exome and whole genome sequencing studies.
These genetic association studies and the efforts of large international consortia, particularly the Psychiatric Genomics Consortium (PGC), have led to the discovery of several bipolar disorder risk variants with genome-wide significant evidence of association. 36 While these discoveries constitute important progress toward a better understanding of the neurobiology of the disease, the studies that produced these results were performed almost exclusively in populations of European ancestry. Very few studies of the genetics of bipolar disorder, and only one published GWAS, have included samples of African ancestry.
That GWAS included only 345 African-American cases, a small number compared with the 1001 European-American cases in the same study, providing inadequate power to detect genetic associations in the African-American subset. 37 The small sample size of the published African-American GWAS of bipolar disorder is in stark contrast to the
TA B L E 1 Studies addressing treatment and drug response in bipolar patients of African ancestry

Study Sample size (N or % total) Major conclusions
Szarek et al. Minimally adequate treatment (defined as use of a mood stabilizer alone or in combination with an antipsychotic) was significantly different in AA vs CA (0% vs 17%; P < .05)
Strickland et al. AA on low-dose lithium (600 mg average dosage), compared with CA, had greater improvement on depression symptoms (P = .04) and improved QOL scores (P = .03)
AA, African-American; CA, Caucasian; ECI, enhanced clinical intervention; HIS, Hispanic; MADRS; the Montgomery-Åsberg Depression Rating Scale; QOL, quality of life; SCBD, specialized care for bipolar disorder.
large number of European ancestry cases that the PGC has accumulated (n = 9784, to date), leading to the discovery of more than a dozen genetic variants contributing to bipolar disorder risk in European populations 38 ( Figure 3) . Similarly, in reviewing GWASs of psychiatric pharmacogenomics, Murphy and McMahon noted that 'non-European groups were underrepresented in these studies'.
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The underrepresentation of individuals of African ancestry in genetic studies is a two-fold issue stemming from both the small numbers of African-ancestry participants and the frequent exclusion of participating minorities from analyses to promote sample homogeneity and prevent confounding by population stratification. The low participation rate of African-Americans in bipolar disorder genetic research speaks to the need to increase engagement of these populations in research;
however, recruitment of African-Americans for genetic research (and bipolar disorder studies more specifically) is challenging 40 ( Table 2) . Surprisingly, the participation rate was lower in European-Americans than in African-Americans (57% vs 71%, respectively; P < .0001). This difference was because willingness to participate was not seen as a major barrier; once reached, minorities were more likely to participate.
Locating minority participants and establishing contact were the key barriers, suggesting that recruitment efforts should focus on areas with a high frequency of individuals of African ancestry.
Another recent study 43 assessed willingness to participate in a biobank, hypothesizing that willingness would be higher under more restrictive scenarios. Participants (n = 13 000; AfricanAmericans = 1483; white individuals = 6521) were randomized to receive a survey in one of three hypothetical biobank scenarios; all scenarios were the same except for consent type and data sharing approach. In this study, African-American participants expressed lower levels of willingness to participate compared to white participants (56% vs 70%, respectively). However, few studies have aimed to understand how to overcome barriers to study participation and inclusion. The STEP-BD created the Community Partner Program (CPP) to address the issue of underrepresented minorities in mental health research studies. Community sites enrolled higher percentages of minority participants when compared to collaborating academic sites (45.2% vs 15.3%, respectively; P < .001). The inception of such programs is essential and demonstrates that including community partners greatly enhances minority involvement in research studies.
Moreover, community-engaged participatory-based research remains crucial to motivating individuals to consistently participate in research activities. 44 These research activities are key to conducting impactful studies that will enhance understanding of the biological and genetic basis of bipolar disorder, which can possibly address previously observed symptomatic differences that lead to misdiagnosis of bipolar African-Americans.
| CON CLUS I ON AND FUTURE DIREC TIONS
This paper has reviewed the racial disparities in bipolar disorder diagnosis, treatment, and research participation, emphasizing the need for increased efforts by the scientific community to address these dis- While this review focused on biological and genetic factors of bipolar disorder, other additional non-biological and historical factors may contribute to this health disparity. Systematic issues such as access to the healthcare system and historical mistrust may also play a role. The mechanisms and processes contributing to this important issue likely involve slavery, institutional racism, discrimination, poverty, and segregation. The focus on genomic and community-based participatory research is meant to be an alternative approach to address these disparities and not reduce the importance of other contributing factors.
We proposed a plan of action to address these disparities that involves understanding the evolution of the problem, and identifying the contribution of associated clinical and biological risk factors of bipolar disorder, particularly through genomic studies. Targeted, biologically based research focused on these differences has the potential to clarify the issues and effect change in the psychiatric care of minority populations. 44 However, low rates of research participation among minority populations compound the problem because low numbers preclude comprehensive evaluation of potential biologic and cultural factors that may contribute to possible differences in clinical presentation and disease progression. Low research participation is best addressed through increased understanding of the barriers to engagement with minority communities as well as strong efforts from the scientific community to include minority persons in studies of bipolar disorder, especially genetic and other etiologic studies. 45 Examples of active engagement efforts include, but are not limited to: community-based participatory research (CBPR) focused on patient and family education, working with faith-based organizations to disseminate impactful and educational research findings, focused efforts to train more psychiatrists in cultural competency, and overall training of more psychiatrists of African ancestry.
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The complexities of the factors that contribute to misdiagnosis of bipolar disorder in individuals of African ancestry and minimal participation from minority samples are critical disparities that warrant attention and action from the scientific community and facilitators.
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TA B L E 2 Participation in genetic studies among subjects of African ancestry AA exhibited more concern about risks to procreation (27% of AA were 'very concerned' compared with 18% of CA; P < .004) and racial discrimination (34% of AA were 'very concerned' compared with 13% of CA; P < .0001)
Hartz et al.
40
Total N = 28 658* AA = 352 cases, 152 controls EA = 705 cases, 710 controls
The participation rate was lower in EA than in AA (57% vs 71%; P < .0001). Mistrust of medical research did not prove to be a barrier for minority participation. Critical barriers were locating minority subjects and establishing contact. Once reached, minorities were more likely to participate AA participants expressed the lowest levels of willingness to participate compared to CA (56% vs 70%)
AA, African-American; CA, Caucasian; EA, European ancestry.*Number screened by phone and filtered through inclusion/exclusion criteria.
